{
  "patientId": "SS001",
  "demographics": {
    "name": "David Miller",
    "dob": "1955-11-30",
    "gender": "Male",
    "ageAtDiagnosis": "69 years old",
    "address": "22 Willow Way, Anytown, USA",
    "phone": "555-2020",
    "insurance": "Medicare",
    "referringPhysician": "Dr. Emily White (Hematology/Oncology)",
    "emergencyContact": "Not specified in record"
  },
  "diagnosis": {
    "primary": "Sézary Syndrome (SS)",
    "datePathologicDiagnosis": "04/15/2024 (Skin Biopsy + Flow Cytometry)",
    "clinicalPresentation": "Generalized erythroderma (>80% BSA), severe pruritus, lymphadenopathy, significant circulating Sézary cells.",
    "tnmbStage": "T4 N1a M0 B2 (Stage IVA1)",
    "priorTreatmentSummary": "Progressive disease despite Extracorporeal Photopheresis (ECP) and Bexarotene.",
    "reasonForCurrentTreatment": "Progressive erythrodermic disease refractory to prior systemic/skin-directed therapy. TSEBT used for rapid disease debulking and symptom control."
  },
  "treatmentPlan": {
    "radOnc": "Dr. Samuel Green",
    "hemeOnc": "Dr. Emily White",
    "treatmentSite": "Total Skin",
    "intent": "Palliative / Disease Debulking",
    "modality": "Total Skin Electron Beam Therapy (TSEBT)",
    "totalDose": "12 Gy",
    "fractionation": "12 fx",
    "rtRxDetails": "12 Gy in 12 fractions (1 Gy/fx, 3x/week over 4 weeks)",
    "targetVolumeSummary": "Entire skin surface",
    "techniqueSummary": "Stanford Technique (6 dual fields)",
    "concurrentChemo": "None",
    "adjuvantSystemicTherapy": "Plan to resume/initiate new systemic therapy (e.g., Mogamulizumab) post-TSEBT based on response.",
    "medications": [
      "Aggressive skin moisturization / Emollients",
      "Topical steroids for localized reactions",
      "Systemic agents for pruritus (e.g., Gabapentin, Mirtazapine)",
      "Antibiotics PRN for skin infections (high risk with erythroderma)"
    ]
  },
  "radiationOncologyData": {
    "ctSimulation": {
      "simulationDate": "01/20/2025",
      "setupInstructions": "Clinical simulation for TSEBT. Patient stands on a rotating platform at an extended distance from the machine. Patient holds various positions to expose all skin surfaces for the 6 dual fields (AP/PA, obliques).",
      "immobilization": "Standing position with support frame/straps.",
      "referenceMarks": "N/A (alignment is to room lasers and patient position, not tattoos).",
      "scanner": "N/A (Clinical setup)",
      "sliceThickness": "N/A",
      "contrastUsed": "N/A",
      "ctNotes": "Patient measured for dose calculations. Setup confirmed. In-vivo dosimetry (TLD/OSLD) placement locations determined to verify dose during treatment. Shielding for eyes and nails designed."
    },
    "dosimetry": {
      "planId": "DMSS001_TSEBT",
      "rx": "12 Gy / 12 fx",
      "technique": "TSEBT",
      "energy": "6 MeV",
      "numberOfFieldsOrArcs": 6,
      "gantryAngles": "Specific TSEBT angles (dual fields from two gantry angles)",
      "collAngles": "Open",
      "couchAngles": "Standing/Rotating",
      "isoCoords": "Extended SSD setup",
      "tps": "Manual Calculation & Verification",
      "algorithm": "Manual/Measured Data",
      "hetero": "No",
      "norm": "Calibration Point",
      "constraints": "Lens dose minimized (<1 Gy)",
      "planNotes": "Low dose TSEBT, 3x/week schedule, for palliative debulking.",
      "fieldDetails": [
        { "fieldName": "AP/PA", "gantryAngle": "Dual Gantry Angles", "energy": "6 MeV", "monitorUnits": "Calibrated per session" },
        { "fieldName": "RAO/LPO", "gantryAngle": "Dual Gantry Angles", "energy": "6 MeV", "monitorUnits": "Calibrated per session" },
        { "fieldName": "LAO/RPO", "gantryAngle": "Dual Gantry Angles", "energy": "6 MeV", "monitorUnits": "Calibrated per session" }
      ]
    },
    "treatmentDelivery": {
      "fractions": [
        { "fractionNumber": 6, "date": "2025-02-03", "machine": "LINAC 1 (TSEBT Mode)", "setupNotes":"Patient setup in all 6 positions. Shields in place. TLDs placed for dose check.", "sideEffects": "Skin remains erythematous, starting to show early desquamation. Pruritus slightly better.", "notes": "Patient reports significant fatigue but is tolerating the setup." },
        { "fractionNumber": 12, "date": "2025-02-17", "machine": "LINAC 1 (TSEBT Mode)", "setupNotes":"Final treatment setup verified.", "sideEffects": "Moderate desquamation. Erythema persistent but less intense. Pruritus significantly improved.", "notes": "Completed final fraction of low-dose TSEBT. Continue intensive skin care." }
      ]
    }
  },
  "imagingAndReports": [
    { "date": "04/15/2024", "type": "Skin Biopsy Report", "summary": "Findings consistent with Sézary Syndrome.", "modalId": "dm-path-report", "reportDetails": { "lab": "Anytown Dermatopathology (Fictional Lab)", "patientInfo": "Miller, David | ID: SS001 | DOB: 11/30/1955", "referringDoctor": "Dr. Emily White (Heme/Onc)", "pathNum": "D-24-1122", "dateObtained": "04/15/2024", "specimen": "Skin Punch Biopsy, Erythrodermic Skin, Back", "diagnosis": "CUTANEOUS T-CELL LYMPHOMA, CONSISTENT WITH SÉZARY SYNDROME (correlate with clinical and hematologic findings).", "microscopicDescription": "Sections show moderately dense superficial dermal lymphocytic infiltrate with prominent epidermotropism, including numerous single atypical lymphocytes and small Pautrier's microabscesses. The lymphocytes are small to medium-sized with markedly convoluted nuclei. Dermal fibrosis is minimal.", "comment": "Findings are compatible with cutaneous involvement by Sézary Syndrome. Correlation with peripheral blood flow cytometry and TCR gene rearrangement studies is recommended.", "signedBy": "Dr. D. Path Fictional, 04/17/2024" } },
    { "date": "01/10/2025", "type": "Clinical Photos", "summary": "Generalized erythroderma (>80% BSA) pre-TSEBT.", "modalId": "dm-clinical-photos", "reportDetails": { "fullSummary": "Photographs document diffuse, generalized erythroderma involving >80% of body surface area. Significant scaling and lichenification present. Excoriations noted secondary to severe pruritus.", "imageSrc": "https://placehold.co/600x400/EEE/31343C?text=Clinical+Photos+SS" } },
    { "date": "01/15/2025", "type": "CT Chest/Abdomen/Pelvis", "summary": "Mild generalized lymphadenopathy, stable from prior. No visceral involvement.", "modalId": "dm-ct-staging", "reportDetails": { "findings": "Mildly prominent but subcentimeter lymph nodes noted in axillary, inguinal, and retroperitoneal regions, likely reactive/dermatopathic given clinical context, stable from prior exam. No hepatosplenomegaly. No suspicious visceral lesions.", "impression": "Mild generalized lymphadenopathy, likely reactive. No definitive evidence of visceral metastatic disease.", "imageSrc": "https://placehold.co/500x500/DDD/525252?text=Staging+CT+Scan" } },
    { "date": "01/20/2025", "type": "TSEBT Simulation/Dosimetry Note", "summary": "Patient measured, setup confirmed for 6-field technique. Low-dose protocol planned.", "modalId": "dm-tsebt-sim", "reportDetails": { "procedure": "Simulation for Low-Dose Total Skin Electron Beam Therapy.", "setup": "Patient positioned standing using Stanford technique setup (6 dual fields). Patient required frequent breaks due to fatigue but setup achieved.", "dosimetry": "Plan calculated for 12 Gy total dose delivered in 12 fractions (1 Gy/fx) over 4 weeks (3 fx/week). In-vivo dosimetry planned.", "shielding": "Custom eye shields, nail shields prepared.", "notes": "Patient educated on low-dose schedule and importance of skin care, especially given erythroderma. Procedure explained.", "imageSrc": "https://placehold.co/600x300/BBB/708090?text=TSEBT+Setup+Diagram" } }
  ],
  "dicomImages": [],
  "labResults": [
    { "date": "01/15/2025", "test": "CBC", "value": "WBC 15.2, Lymph 65%", "notes": "Lymphocytosis" },
    { "date": "01/15/2025", "test": "CMP", "value": "WNL", "notes": "Baseline" },
    { "date": "01/15/2025", "test": "LDH", "value": "350", "units": "U/L", "range": "140-280", "notes": "Elevated - Marker of disease activity" },
    { "date": "01/15/2025", "test": "Sézary Count (Flow Cytometry)", "value": "3500 cells/µL (CD4+/CD7-)", "range": "<1000", "notes": "Confirms B2 status (High blood burden)" },
    { "date": "01/15/2025", "test": "TCR Gene Rearrangement (Blood)", "value": "Clonal population detected", "notes": "Confirms circulating clone" }
  ],
  "progressNotes": [
    { "date": "01/08/2025", "author": "Dr. Emily White (Heme/Onc)", "type": "Progress Note", "summary": "Pt with known SS, progressive erythroderma and worsening pruritus despite ECP + Bexarotene. Discussed further options including other systemic agents vs TSEBT for rapid debulking/symptom control. Refer to Rad Onc for TSEBT consult." },
    { "date": "01/16/2025", "author": "Dr. Samuel Green (Rad Onc)", "type": "Initial Consult", "summary": "Pt referred for TSEBT for refractory Stage IVA1 SS. Exam confirms T4 erythroderma. Discussed low-dose TSEBT (12 Gy) for palliation and debulking prior to potentially starting new systemic agent. Explained procedure, high risk of skin toxicity/infection in erythrodermic state, need for intensive skin care. Pt understands and wishes to proceed. Sim scheduled." },
    { "date": "01/20/2025", "author": "Nursing/RT Ed", "type": "TSEBT Education", "summary": "Emphasis on skin care (moisturizers, gentle cleansing, bleach baths if recommended), infection prevention, managing fatigue. Schedule reviewed." },
    { "date": "02/03/2025", "author": "Dr. Samuel Green (Rad Onc)", "type": "OTV - Week 2", "summary": "Completed 6/12 fx. Skin remains erythematous, starting to show early desquamation. Pruritus slightly better. Tolerating daily setup. Continue low-dose TSEBT. Monitor closely for infection." },
    { "date": "02/17/2025", "author": "Dr. Samuel Green (Rad Onc)", "type": "OTV - End of Treatment", "summary": "Completed 12/12 fx low-dose TSEBT. Moderate desquamation, particularly in folds. Erythema persistent but less intense. Pruritus significantly improved. Plan for continued intensive skin care. Follow up with Heme/Onc to discuss next systemic therapy." }
  ],
  "patientEducation": {
    "goalsDiscussed": "Palliative treatment to reduce the total amount of lymphoma in the body (debulking), control the severe skin redness and scaling (erythroderma), and improve itching.",
    "sideEffectsReviewed": "A significant, whole-body skin reaction, even with low dose. This includes redness, dryness, and peeling. Risk of skin infection is high due to pre-existing erythroderma. Fatigue is expected. Hair thinning/loss and nail changes are possible but may be less severe than with standard dose.",
    "safetyConsiderations": "Aggressive, gentle skin care (frequent moisturizing, avoiding irritants) is critical. Reporting any signs of skin infection (fever, pus, increased pain) immediately is essential.",
    "patientResponsibilities": "Attend all treatments (3x/week for 4 weeks). Adhere strictly to the skin care regimen. Monitor for infection.",
    "medicationCompliance": "Use supportive medications for itching and skin care as prescribed."
  },
  "scheduling": [
    { "date": "01/15/2025", "time": "9 AM", "type": "Staging CT C/A/P", "location": "Radiology", "status": "Completed" },
    { "date": "01/16/2025", "time": "10 AM", "type": "Rad Onc Consult (Green)", "location": "Rad Onc Clinic", "status": "Completed" },
    { "date": "01/20/2025", "time": "1 PM", "type": "TSEBT Simulation", "location": "Rad Onc Sim", "status": "Completed" },
    { "date": "01/27/2025 - ~02/21/2025", "time": "Daily (M/W/F) ~11 AM", "type": "Low Dose TSEBT Treatment (1/12)", "location": "LINAC 1 (TSEBT Mode)", "status": "Completed" },
    { "date": "Weekly", "time": "~11:30 AM (Post-RT)", "type": "OTV / Skin Check", "location": "Rad Onc Clinic", "status": "Completed" },
    { "date": "~03/01/2025", "time": "10 AM", "type": "Heme/Onc Follow Up", "location": "Oncology Clinic", "status": "Scheduled" }
  ],
  "cptCharges": [
    { "code": "77285 / 77290", "description": "Simulation, Intermediate / Complex", "frequency": "Once" },
    { "code": "77334", "description": "Treatment device, Complex (Shielding blocks)", "frequency": "Once per course" },
    { "code": "77300", "description": "Basic radiation dosimetry calculation (TLD measurements)", "frequency": "Weekly/Per Course" },
    { "code": "77331", "description": "Special physics consultation (TSEBT planning)", "frequency": "Once" },
    { "code": "77422", "description": "Total skin electron therapy", "frequency": "Per Session (3x/week)" },
    { "code": "77427", "description": "Radiation treatment management, 5 treatments", "frequency": "Weekly (x4)" }
  ],
  "diagnosisSearch": "Sézary Syndrome"
}